There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enlivex (ENLV – Research Report), Replimune Group (REPL – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments.
Enlivex (ENLV)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Enlivex today and set a price target of $15.00. The company’s shares closed last Monday at $2.56, close to its 52-week low of $2.17.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Enlivex has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
See Insiders’ Hot Stocks on TipRanks >>
Replimune Group (REPL)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group, with a price target of $51.00. The company’s shares closed last Monday at $21.07.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Replimune Group has an analyst consensus of Strong Buy, with a price target consensus of $56.14, a 175.5% upside from current levels. In a report issued on July 28, BMO Capital also assigned a Buy rating to the stock with a $70.00 price target.
Ultragenyx Pharmaceutical (RARE)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $82.00. The company’s shares closed last Monday at $43.12.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $89.31 average price target, representing a 105.5% upside. In a report issued on July 24, Piper Sandler also assigned a Buy rating to the stock with a $130.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ENLV:
